The ICH has released a draft consolidated guideline (ICH Q1) that unifies the previous Q1A–Q1F series into a single global standard. This revision simplifies stability requirements, integrates lifecycle management, and expands the scope to advanced therapies and drug-device combinations.
This whitepaper provides a clear overview of the key changes — from predictive tools and modeling to stability expectations for ATMPs and critical auxiliary materials.
Download the full whitepaper to explore how the new guideline impacts your development and regulatory strategy
Thank you for your interest in our scientific content.
